Mark Johnson | Vice President, Investor Relations |
Steve Davis | Chief Executive Officer |
Mark Schneyer | Chief Financial Officer |
Brendan Teehan | Chief Operating Officer, Head, Commercial |
Kathie Bishop | Chief Scientific Officer and Head, Rare Disease |
Doug Williamson | Head, Research and Development |
Ritu Baral | Cowen |
Tessa Romero | J.P. Morgan |
Marc Goodman | SVB Leerink |
Tazeen Ahmad | Bank of America Merrill Lynch |
Charles Duncan | Cantor Fitzgerald |
Neena Bitritto-Garg | Citi |
Eddie Hickman | Guggenheim Partners |
Gregory Renza | RBC Capital |
Jeff Hung | Morgan Stanley |
Jay Olson | Oppenheimer |
David Hoang | SMBC Nikko |
Kyle Qian | Canaccord Genuity |
Good day, ladies and gentlemen. And welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today. At this time, all participants are in listen-only mode.
We will be facilitating a question-and-answer session towards the end of today’s call.